As such, the use of HDAC6 inhibitors to alleviate tau burden through the enhanced acetylation on KXGS motifs represents a very promising therapeutic strategy that should be investigated as a potential treatment for AD, as well as other tauopathies, including chronic traumatic encephalopathy. This evidence concerns the gene HDAC6 and Alzheimer disease.